CMED and Tessella Partner on Adaptive Clinical Trials
Companies Partner to Reduce Risk and Time in Design and Execution of Adaptive Clinical Trials for Bio-Tech and Pharmaceutical Companies
CMED and Tessella Partner on Adaptive Clinical Trials
Cmed, the leading clinical research organization and technology development company, has entered into a partnership agreement with Tessella, the information technology and consulting services company selected by R&D, science and engineering leaders for business-critical assignments. Under the terms of the agreement, Tessella and Cmed will ensure interoperability of Timaeus, the Intelligent Data Acquisition and Management system (iDAM) with Tessella FATES™, Tessella’s fixed and adaptive trial execution system.
“With Timaeus, organizations have the ability to acquire, manage and report data in near real-time. This is particularly important for adaptive trials because it minimizes the delay in the availability of response data and therefore adaptation of the trial,” said Tom Parke, head of clinical technologies at Tessella. Parke added, “The interoperability of two best of breed clinical trial products represents an important step in removing the operational complexity associated with adaptive clinical trials.”
Richard Young, Director of Business Development at Cmed said: “Tessella and Cmed have been collaborating for some time; not least of all through our Adaptive Trial Design symposium (February 2009). By entering into a partnership this will reinforce our capabilities, and provide unparalleled solutions for adaptive designs .” Young continues: “Tessella bring huge experience in the design, simulation and execution of adaptive trial designs and the interoperability of Tessella FATES and Timaeus enables bio-tech and pharma companies the ability to leverage this knowhow.”
Notes to Editors:
About CMED
Cmed is an eCRO, based in Horsham, UK, New Jersey, USA and Timisoara, Romania. Cmed was formed by Pharmaceutical industry executives and it uniquely combines full clinical research services with advanced clinical data capture and management technology, Timaeus, developed by Cmed's own technology company. Timaeus is a sophisticated and complete electronic data capture and management system, the first such system enabling multiple types of data capture within a single trial (including paper, web eDC and an advanced wireless eDC appliance) with full data management capabilities. The eDC appliance is even capable of direct data capture from medical devices, e-source support etc.
Further information is available at www.cmedresearch.com
About Tessella
For decades, Tessella has been successfully delivering IT and consulting services to world leaders in R&D, science and engineering. Through the application of scientific methods and rigorous quality procedures, we enable clients in life sciences, energy, the public sector, and consumer industries to achieve a wide range of objectives, including forecasting floods, developing fusion power, enhancing military sensor capability, improving drug discovery and development efficiency, and reducing risk to health and the environment in the extraction and production of oil and gas. With offices in Europe and North America, global companies rely on Tessella for business critical assignments.
Further information is available at www.tessella.com
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5954585&lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Tessella
Christina Tealdi
Marcomms & PR Exec
Phone:
+44-(0)-1235-555511
christina.tealdi@tessella.com
or
Cmed
Jane
Stubbington
Marketing Communications Manager
Phone:
+44-(0)-1403-755050
jstubbington@cmedresearch.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom